CD19 is a pan B-cell surface receptor expressed from pro-B-cell development until its down-regulation during terminal differentiation into plasma cells. CD19 represents an attractive immunotherapy target for cancers of lymphoid origin due to its high expression levels on the vast majority of non-Hodgkin's lymphomas and some leukemias. A humanized anti-CD19 antibody with an engineered Fc domain (XmAb5574) was generated to increase binding to Fc; receptors on immune cells and thus increase Fc-mediated effector functions. In vitro, XmAb5574 enhanced antibodydependent cell-mediated cytotoxicity 100-fold to 1,000-fold relative to an anti-CD19 IgG1 analogue against a broad range of B-lymphoma and leukemia cell lines. Furthermore, XmAb5574 conferred antibody-dependent cell-mediated cytotoxicity against patient-derived acute lymphoblastic leukemia and mantle cell lymphoma cells, whereas the IgG1 analogue was inactive. XmAb5574 also increased antibody-dependent cellular phagocytosis and apoptosis. In vivo, XmAb5574 significantly inhibited lymphoma growth in prophylactic and established mouse xenograft models, and showed more potent antitumor activity than its IgG1 analogue. Comparisons with a variant incapable of Fc; receptor binding showed that engagement of these receptors is critical for optimal antitumor efficacy. These results suggest that XmAb5574 exhibits potent tumor cytotoxicity via direct and indirect effector functions and thus warrants clinical evaluation as an immunotherapeutic for CD19 + hematologic malignancies.
The human kallikreins are a large multigene family of closely related serine-type proteases. In this regard, they are similar to the multigene kallikrein families characterized in mice and rats. There is a much more extensive body of knowledge regarding the function of mouse and rat kallikreins in comparison with the human kallikreins. Human kallikrein 6 has been proposed as the homologue to rat myelencephalon-specific protease, an arginine-specific degradative-type protease abundantly expressed in the central nervous system and implicated in demyelinating disease. We present the xray crystal structure of mature, active recombinant human kallikrein 6 at 1.75-Å resolution. This high resolution model provides the first three-dimensional view of one of the human kallikreins and one of only a few structures of serine proteases predominantly expressed in the central nervous system. Enzymatic data are presented that support the identification of human kallikrein 6 as the functional homologue of rat myelencephalon-specific protease and are corroborated by a molecular phylogenetic analysis. Furthermore, the xray data provide support for the characterization of human kallikrein 6 as a degradative protease with structural features more similar to trypsin than the regulatory kallikreins.Recent studies demonstrate that humans have a large multigene family of at least 15 different kallikreins (serine type proteases, abbreviated as KLK 1 in reference to the gene, or hK in reference to the protein) (1). Similarly, the mouse and rat kallikrein gene families are characterized by a large number of closely related members that presumably arose because of gene duplication events (2-6). The different members of the mouse and rat kallikreins are characterized by a high degree of amino acid identity, but typically exhibit different preferences toward peptide substrates (7-12). Several human kallikreins have been identified as potentially useful diagnostic markers for breast (KLK3 and KLK6), prostate (KLK2 and KLK3), and ovarian (KLK6, KLK9, KLK10, and KLK11) cancers as well as neurodegenerative diseases such as Alzheimer's (KLK6) (1, 13-17).Myelencephalon-specific protease (MSP) is a member of the rat kallikrein gene family that is abundantly expressed in the rodent central nervous system and shown to be up-regulated in response to glutamate receptor-mediated excitotoxic injury (18). Potential human homologues to rat MSP have also been identified (18) and have been alternatively named protease M (19), Zyme (20), and neurosin (21). Mouse homologues to MSP have been reported as brain and skin serine protease (BSSP) (22) and brain serine protease (BSP) (23). It has been postulated that MSP/protease M/neurosin may play a key role in the regulation of myelin turnover and in demyelinating disease (18, 24 -27), including the development of multiple sclerosis lesions (25). Furthermore, this kallikrein may also play a role in the degradation of -amyloid or turnover of amyloid precursor protein (28,29). The kinetic properties of MSP have ident...
Kallikrein 6 (K6, MSP) is a newly identified member of the Kallikrein family of serine proteases that is preferentially expressed in the adult central nervous system (CNS). We have previously demonstrated that K6 is abundantly expressed by inflammatory cells at sites of CNS inflammation and demyelination in animal models of multiple sclerosis (MS) and in human MS lesions. To test the hypothesis that this novel enzyme is a mediator of pathogenesis in CNS inflammatory disease, we have evaluated whether autonomously generated K6 antibodies alter the clinicopathological course of disease in murine proteolipid protein139-151-induced experimental autoimmune encephalomyelitis (PLP139-151 EAE). We demonstrate that immunization of mice with recombinant K6 generates antibodies that block K6 enzymatic activity in vitro, including the breakdown of myelin basic protein (MBP), and that K6-immunized mice exhibit significantly delayed onset and severity of clinical deficits. Reduced clinical deficits were reflected in significantly less spinal cord pathology and meningeal inflammation and in reduced Th1 cellular responses in vivo and in vitro. These data demonstrate for the first time that K6 participates in enzymatic cascades mediating CNS inflammatory disease and that this unique enzyme may represent a novel therapeutic target for the treatment of progressive inflammatory disorders, including MS.
Myelencephalon-specific protease (MSP), first identified in the rat and now known to have a human homologue (human kallikrein 6), is preferentially expressed in the central nervous system (CNS), compared with nonneural tissues. MSP has been postulated to have trypsin-like activity, is upregulated in response to glutamate receptor-mediated excitotoxic injury in the CNS, and is downregulated in the brain of Alzheimer's patients. The preferential expression of this enzyme by oligodendrocytes in CNS white matter points to a role in myelin homeostasis. To further characterize the activity and substrate specificity of this newly identified enzyme, we have heterologously expressed MSP in a baculovirus/insect cell line system. We demonstrate that recombinant MSP exhibits a broad specificity for cleavage after arginine but not lysine residues, with kinetic characteristics intermediate between trypsin and pancreatic kallikrein. We show that the pro form of MSP does not self-activate but, rather, requires cleavage after lysine, indicating that mature active MSP is regulated by a distinct protease. MSP may be regulated in part by autolysis, since the active protein is readily inactivated through autolysis at specific internal arginine positions. Additionally, we show that MSP is abundantly expressed in inflammatory cells at sites of demyelination in the Theiler's murine encephalomyelitis virus (TMEV) model of multiple sclerosis (MS). In conjunction with data demonstrating the ability of MSP to degrade myelin-associated as well as several extracellular matrix proteins, these findings delineate MSP as a broad-specificity arginine-specific protease with the potential to play a key role in immune-mediated demyelination.
Purpose: Despite advances in the treatment of multiple myeloma, new therapies are needed to induce more profound clinical responses. T-cell-redirected lysis triggered by bispecific antibodies recruiting T cells to cancer cells is a clinically validated mechanism of action against hematologic malignancies and CD38 is a tumor-associated antigen with near-universal expression in multiple myeloma. Thus, an anti-CD38/CD3 bispecific T-cell-recruiting antibody has the potential to be an effective new therapeutic for multiple myeloma. Experimental Design: Anti-CD38/CD3 XmAb T-cellrecruiting antibodies with different affinities for CD38 and CD3 were assessed in vitro and in vivo for their redirected T-cell lysis activity against cancer cell lines, their lower levels of cytokine release, and their potency in the presence of high levels of soluble CD38. Select candidates were further tested in cynomolgus monkeys for B-cell depletion and cytokine release properties. Results: AMG 424 was selected on the basis of its ability to kill cancer cells expressing high and low levels of CD38 in vitro and trigger T-cell proliferation, but with attenuated cytokine release. In vivo, AMG 424 induces tumor growth inhibition in bone marrow-invasive mouse cancer models and the depletion of peripheral B cells in cynomolgus monkeys, without triggering excessive cytokine release. The activity of AMG 424 against normal immune cells expressing CD38 is also presented. Conclusions: These findings support the clinical development of AMG 424, an affinity-optimized T-cell-recruiting antibody with the potential to elicit significant clinical activity in patients with multiple myeloma.
IntroductionIn the past decade, monoclonal antibodies directed against B-cell antigens have proven beneficial for patients with B-lineage neoplasms. Approved immunotherapeutics include the anti-CD52 antibody alemtuzumab (Campath-1H), 1 2 anti-CD20 antibodies, rituximab (Rituxan) 2 and most recently ofatumumab (Arzerra), 3 and 2 anti-CD20 conjugates carrying radioactive isotopes, 90 Yibritumomab tiuxetan (Zevalin) 4 and 131 I-tositumomab (Bexxar). 5 In particular, when used as a single agent or in combination with chemotherapy, rituximab has shown efficacy and relative safety in many B-cell non-Hodgkin lymphomas (NHLs) and some B-cell leukemias. 2,6 However, some patients do not respond to rituximab, and many of those that do will relapse. 2 In addition, some B-cell tumors either lack CD20 expression or lose it during rituximab treatment. 7 Thus, antibodies targeting other B-cell antigens are warranted, and several are being explored, including those targeting CD40, a 45-to 50-kDa transmembrane glycoprotein belonging to the tumor necrosis factor receptor family.CD40 is broadly expressed on hematologic cells, including B cells and on several types of epithelial and endothelial cells. [8][9][10] The ligand of CD40, CD40L (CD154), is preferentially expressed on activated T cells but has also been found on other hematologic cell types. Signaling via the CD40 pathway plays a key role in defining cellular and humoral immune responses. 10 CD40 is overexpressed by the malignant counterparts to Blineage cells and is found on most mature B-cell malignancies, including NHL, Hodgkin disease, and chronic lymphocytic leukemia (CLL), and on some early acute lymphocytic leukemias (ALL) 8,11,12 ; it is also expressed on multiple myeloma (MM) cells. 13 Many solid tumors express CD40, including melanoma and carcinomas of the kidney, bladder, lung, pancreas, colon, prostate, ovary, breast, head, and neck. 14 CD40 agonists have been shown to trigger immune responses against various tumors 15,16 and to inhibit the growth of different neoplastic cells, both in vitro and in vivo. 17,18 Broad stimulation of the immune system and expression on a wide range of malignancies make CD40 an attractive target for antibody-based immunotherapy. Over the past 2 decades, several CD40-specific antibodies have been tested against B-lineage malignancies in vitro and in animal models, yielding various degrees of success. [19][20][21][22][23] Recently, 2 humanized antibodies have emerged for further development: a mild CD40 agonist, 20,24,25 and a CD40 antagonist, HCD122 (CHIR-12.12). 21,23 These agents were evaluated in phase 1 and 2 trials in patients with relapsed MM, NHL, and CLL. Thus far, they have demonstrated a favorable safety profile and have shown some antitumor activity in NHL and MM. [26][27][28] In addition, a strongly agonistic anti-CD40 antibody, CP-870,893, evaluated in phase 1 trials in patients with melanoma and other solid tumors, was found to be well tolerated and to have antitumor activity. 29 Therefore, preclinical and early clinic...
A 1.10-A atomic resolution X-ray structure of human fibroblast growth factor 1 (FGF-1), a member of the beta-trefoil superfold, has been determined. The beta-trefoil is one of 10 fundamental protein superfolds and is the only superfold to exhibit 3-fold structural symmetry (comprising 3 "trefoil" units). The quality of the diffraction data permits unambiguous assignment of Asn, Gln, and His rotamers, Pro ring pucker, as well as refinement of atomic anisotropic displacement parameters (ADPs). The FGF-1 structure exhibits numerous core-packing defects, detectable using a 1.0-A probe radius. In addition to contributing to the relatively low thermal stability of FGF-1, these defects may also permit domain motions within the structure. The availability of refined ADPs allows a translation/libration/screw (TLS) analysis of putative rigid body domains. The TLS analysis shows that beta-strands 6-12 together form a rigid body, and there is a clear demarcation in TLS motions between the adjacent carboxyl- and amino-termini. Although separate from beta-strands 6-12, the individual beta-strands 1-5 do not exhibit correlated motions; thus, this region appears to be comparatively flexible. The heparin-binding contacts of FGF-1 are located within beta-strands 6-12; conversely, a significant portion of the receptor-binding contacts are located within beta-strands 1-5. Thus, the observed rigid body motion in FGF-1 appears related to the ligand-binding functionalities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.